NCT06064422

Brief Summary

The present study aims to adapt and evaluate the feasibility of the BeatIt-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 25, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 3, 2023

Completed
29 days until next milestone

Study Start

First participant enrolled

November 1, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2025

Completed
Last Updated

May 4, 2026

Status Verified

April 1, 2026

Enrollment Period

1.8 years

First QC Date

September 25, 2023

Last Update Submit

April 30, 2026

Conditions

Keywords

behavioral activation

Outcome Measures

Primary Outcomes (3)

  • Glasgow Depression Scale for Intellectual Disability (GDS)

    The GDS is a 20-item self- and caregiver-reported questionnaire of psychological function over the past week with all items on a "0" (Never/No) to 2 (Always/A lot) scale. Higher scores equal more distress. Scores range from 0-32. The expected change is a decrease in the score.

    Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)

  • Anxiety Depression and Mood Scale (ADAMS)

    The ADAMS is a 20-item caregiver-reported questionnaire of psychological function over the past week with all items on a "0" (Never/No) to 2 (Always/A lot) scale. Higher scores equal more distress. Total scores range from 0-84. The expected change is a decrease in the score.

    Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)

  • Mood, Interest, & Pleasure Questionnaire (MIPQ)

    The MIPQ is a 25-item caregiver-reported questionnaire of behaviors over the past week with all items on a "0" (Never) to 4 (All the time) scale. Higher scores equal more distress. Total scores range from 0-100. The expected change is a decrease in the score.

    Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)

Secondary Outcomes (2)

  • Vineland Adaptive Behavior Scale, 3rd edition (VABS-3)

    Week 1 (initial assessment) to week 22 (follow-up)

  • Shalock Quality of Life Questionnaire

    Week 1 (initial assessment) to week 16 (outcome) to week 22 (follow-up)

Study Arms (1)

BeatIt-MV Treatment Group

EXPERIMENTAL

Participants, along with support persons, will complete 12 weekly sessions of the BeatIt-MV intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.

Behavioral: BeatIt-MV

Interventions

BeatIt-MVBEHAVIORAL

BeatIt-MV, designed to be implemented with minimally verbal autistic individuals, is an adaptation of BeatIt-2. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.

BeatIt-MV Treatment Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Minimally verbal
  • Aged 18 years or older
  • Diagnosis of Autism Spectrum Disorder and clinically significant depression based on clinical best estimate diagnosis using DSM-5 or Diagnostic Manual - Intellectual Disability criteria
  • Have a support person willing to participate
  • Live in New Jersey or New York, or be within travel distance to Rutgers University

You may not qualify if:

  • Not able to engage in treatment in English
  • current engagement in other treatment for depression
  • conditions that may preclude engagement in treatment sessions (e.g., active psychosis, unmanaged seizures)
  • high suicide risk (i.e., with a clear plan, expressed intent or recent documented attempts)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rutgers University - New Brunswick

Piscataway, New Jersey, 08854, United States

Location

MeSH Terms

Conditions

Autistic DisorderDepressionAutism Spectrum Disorder

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental DisordersBehavioral SymptomsBehavior

Study Officials

  • Vanessa Bal, PhD

    Rutgers University - New Brunswick

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor; Karmazin & Lillard Chair in Adult Autism, Rutgers, The State University of New Jersey

Study Record Dates

First Submitted

September 25, 2023

First Posted

October 3, 2023

Study Start

November 1, 2023

Primary Completion

August 30, 2025

Study Completion

August 30, 2025

Last Updated

May 4, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations